|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 24, 2017 ) Multiple myeloma is a specifically fatal but less common type of blood cancer effects in eventual patient deteriorations even after therapy and is universally considered as lethal. Incidence of multiple myeloma is increasing with each passing year. The disease mostly affects the aged, assumed the average age of disease start at around 70 years.
View Full Report @ http://www.marketdataforecast.com/market-reports/latin-america-multiple-myeloma-therapeutics-market-862/
Expanding indications of existing drugs, emergence of new and promising drugs, increasing incidence of multiple myeloma and increasing use of drugs already on the market are fuelling growth of the market. Moreover, growth is being driven by the drive to novel drugs in search of higher effectiveness and safety and increasing use of these high prices medicines for the treatment of the condition. Stringent regulation is the key factor hindering the multiple myeloma therapeutics market.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/latin-america-multiple-myeloma-therapeutics-market-862/request-sample
The Latin America Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)). With the advancement in technology targeted therapy is on a high growth due to its advantages over chemotherapy such as lesser side effects.
Inquire before buying @ http://www.marketdataforecast.com/market-reports/latin-america-multiple-myeloma-therapeutics-market-862/inquire
Based on geography the market is analysed under various regions namely, Brazil, Argentina and Mexico. Mexico is dominating the multiple myeloma therapeutics market in the Latin America region and is expected to continue its dominance over the forecast period.
Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson.
About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and sksillset dedicatedly serve clients from various industries and regions.
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
